%0 Journal Article
%A Garassino, Marina Chiara
%A Cho, Byoung-Chul
%A Kim, Joo-Hang
%A Mazières, Julien
%A Vansteenkiste, Johan
%A Lena, Hervé
%A Jaime, Jesus Corral
%A Gray, Jhanelle E
%A Powderly, John
%A Chouaid, Christos
%A Bidoli, Paolo
%A Wheatley-Price, Paul
%A Park, Keunchil
%A Soo, Ross A
%A Poole, Lynne
%A Wadsworth, Catherine
%A Dennis, Phillip A
%A Rizvi, Naiyer A
%T Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.
%D 2020
%U http://hdl.handle.net/10668/15981
%X In the phase II ATLANTIC study, durvalumab provided durable responses with acceptable tolerability in heavily pretreated patients with advanced NSCLC, across three independent patient cohorts defined by EGFR/ALK status and tumour PD-L1 expression. Preliminary overall survival (OS) data were encouraging. We now report final OS and updated safety data. Patients with advanced NSCLC with disease progression following ≥2 previous systemic regimens received durvalumab 10 mg/kg every 2 weeks. The primary endpoint was objective response rate among patients with increased PD-L1 expression (defined as ≥25 % or ≥90 % of tumour cells [TCs], cohort-dependent). Secondary endpoints included OS and safety. 444 patients received durvalumab: 111 in Cohort 1 (EGFR+/ALK+), 265 in Cohort 2 (EGFR-/ALK-), and 68 in Cohort 3 (EGFR-/ALK-; TC ≥ 90 %). Median (95 % CI) OS was 13.3 months (6.3-24.5) in patients with EGFR+/ALK+ NSCLC with TC ≥ 25 %, 10.9 months (8.6-13.6) in patients with EGFR-/ALK- NSCLC with TC ≥ 25 %, and 13.2 months (5.9-not reached) in patients with EGFR-/ALK- NSCLC with TC ≥ 90 %. Median (95 % CI) OS was slightly shorter in patients with TC  After additional follow-up, final OS data remain encouraging across all cohorts, further supporting the clinical activity of durvalumab in patients with heavily pretreated advanced NSCLC, including those with EGFR+/ALK+ tumours. There were no new safety signals.
%K ATLANTIC
%K Durvalumab
%K NSCLC
%K Overall survival
%K Safety
%~